Preclinical studies further show that the engager increases NK-cell cytotoxicity against GBM cells with high IL-13Rα2 expression, induces mitochondrial-pathway apoptosis, and markedly elevates CD25/CD69 expression and caspase-3 activity. This evidence concerns the gene IL13RA2 and glioblastoma.